8-K: Achieve Life Sciences Appoints New Directors
Director Appointment
Achieve Life Sciences, Inc. announced the appointment of two new directors to its Board, effective May 29, 2026.
Summary
- Achieve Life Sciences, Inc. has appointed Jeff Farrow and Dr. Reid Waldman to its Board of Directors, effective May 29, 2026.
- Mr. Farrow will serve on the Nominating and Governance Committee and as Chair of the Audit Committee.
- Dr. Waldman will join the Commercial Committee and serve as Chair of the Compensation Committee.
- Both new directors will receive a pro-rated annual retainer of $40,000 for the fiscal year ending December 31, 2026, plus additional compensation for committee service.
- They will also each receive stock options to purchase 47,250 shares of common stock, vesting monthly over three years.
- Standard indemnification agreements have been entered into with the new directors.
Sentiment
Score: 6
Explanation: StockSavvy.ai views this as a neutral to slightly positive development, indicating proactive board management and governance enhancement, but without immediate financial impact.
Positives
- Strengthens the Board of Directors with new expertise.
- New directors appointed to key committees, including Audit and Compensation.
- Standard compensation structure for non-employee directors is being applied.
- Stock options incentivize long-term commitment from new directors.
Risks
- The effectiveness of the new directors in their roles and committee leadership is yet to be determined.
- The vesting schedule for stock options implies a need for continued service, which is not guaranteed.
Future Outlook
The appointment of new directors is intended to strengthen the Board's oversight and strategic guidance, with compensation structured to align with long-term company performance through stock options.
Industry Context
StockSavvy.ai notes that the appointment of new directors to key committees like Audit and Compensation is a common practice for companies seeking to enhance corporate governance and specialized oversight, particularly as they navigate growth or strategic shifts.
Management Changes
| Role | Previous Person | New Person | Effective Date | Reason |
|---|---|---|---|---|
| Director | N/A | Jeff Farrow | 2026-05-29 | Appointment to enhance Board expertise and oversight. |
| Director | N/A | Reid Waldman, M.D. | 2026-05-29 | Appointment to enhance Board expertise and oversight. |
| Member, Nominating and Governance Committee | N/A | Jeff Farrow | 2026-05-29 | Appointment to committee. |
| Chair, Audit Committee | N/A | Jeff Farrow | 2026-05-29 | Appointment to committee chair. |
| Member, Commercial Committee | N/A | Reid Waldman, M.D. | 2026-05-29 | Appointment to committee. |
| Chair, Compensation Committee | N/A | Reid Waldman, M.D. | 2026-05-29 | Appointment to committee chair. |
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Board Composition | Appointment of two new directors, Jeff Farrow and Reid Waldman, M.D., to the Board of Directors. | 2026-05-29 | Enhances board diversity of skills and experience, strengthens committee leadership. |
| Committee Appointments | Jeff Farrow appointed to Nominating and Governance Committee and as Chair of the Audit Committee. Reid Waldman, M.D. appointed to Commercial Committee and as Chair of the Compensation Committee. | 2026-05-29 | Strengthens oversight in critical areas of governance, financial reporting, and executive compensation. |
Stakeholder Impact
- Shareholders: Potential for improved corporate governance and strategic direction due to new board expertise.
- Employees: Indirect impact through enhanced board oversight and strategic decision-making.
- Creditors: Indirect impact through improved financial oversight and governance.
Next Steps
- New directors will commence their duties on the Board and respective committees.
- Vesting of stock options for new directors will occur monthly over three years, subject to continued service.
Key Dates
| Date | Description |
|---|---|
| 2025-12-31 | Year ended December 31, 2025 (referenced for indemnification agreement filing). |
| 2026-05-29 | Effective date of appointment for new directors Jeff Farrow and Reid Waldman, M.D. |
| 2026-12-31 | Fiscal year ending December 31, 2026 (for pro-rated director retainer calculation). |
| 2026-06-02 | Date of report filing. |
Keywords
Achieve Life Sciences, Board of Directors, Director Appointment, Audit Committee, Compensation Committee, Nominating and Governance Committee, Stock Options, Corporate Governance
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.